OmnigenicsAI Corp Watch

from F-4/A 4 pages Certain Confidential Information in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed

from F-4/A 2 pages Reference Is Made to That Certain (I) Engagement Letter Between Earlybirdcapital, Inc. (“Ebc”) and APx Acquisition Corp. I (The “Company”) Dated October 17, 2022 (The “Placement Engagement Letter”) and (II) Business Combination Marketing Agreement Between Ebc and the Company Dated October 17, 2022 (The “Bcma”). 1. Ebc and the Company Hereby Agree That the Placement Engagement Letter Is Terminated; Provided That the Provisions Concerning Confidentiality, Indemnification and Contribution Shall Survive the Termination Provided for Herein. 2. Ebc and the Company Hereby Agree That the Bcma Is Amended as Follows: A. the Term “Target” as Defined in the Introductory Paragraph of the Bcma Shall Hereafter Refer to Any Target Business With Which the Company Seeks to Consummate a Business Combination (As Defined in the Bcma). B. Section 1(b) of the Bcma Is Hereby Amended and Restated to Read

from F-4/A 7 pages Earlybirdcapital, Inc. 366 Madison Avenue New York, Ny 10017 Member Finra Sipc

from F-4/A 7 pages Earlybirdcapital, Inc. 366 Madison Avenue – 8th Floor New York, Ny 10017 Member Finra Sipc

from F-4/A 36 pages Form of Registration Rights and Lock-Up Agreement

from F-4 5 pages Re: Proposed Addendum No. 1 to Service Lease Offer No. 01/2024

from F-4 22 pages Certain Confidential Information in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed

from F-4 3 pages Addendum N° 1 to the Commercialization Agreement Between Heritas S.A. and Centro De Diagnóstico Médico De Alta Complejidad S.A. Dated January 3, 2017

from F-4 11 pages Annex a Terms and Conditions Commercialization Offering

from F-4 6 pages This Document Constitutes a Binding Summary of Terms and Conditions (Hereinafter, the “Ts”) of a Reseller License Agreement to Be Executed by and Between Multiplai Health Ltd and Omnigenicsai Corp. (The “Transaction”)